NCT06759181View on ClinicalTrials.gov

Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 10, 2027

Study Completion Date

December 31, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

anti-BCMA/FcRL5 CAR T

"anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:"

Trial Locations (1)

Unknown

RECRUITING

Xuzhou, Xuzhou

All Listed Sponsors

lead

Xuzhou Medical University

OTHER